Avacta Group Yönetim

Yönetim kriter kontrolleri 1/4

Avacta Group CEO'su Chris Coughlin, May2024 tarihinde atandı, in görev süresi bir yıldan az. şirketin hisselerinin 0.014% doğrudan sahiptir ve bu hisselerin değeri € 31.66K dir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 1.6 yıl ve 0.3 yıldır.

Anahtar bilgiler

Chris Coughlin

İcra Kurulu Başkanı

UK£53.0k

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	less than a year
CEO sahipliği	0.01%
Yönetim ortalama görev süresi	1.6yrs
Yönetim Kurulu ortalama görev süresi	less than a year

Son yönetim güncellemeleri

Recent updates

CEO

Chris Coughlin (54 yo)

less than a year

Görev süresi

UK£53,000

Tazminat

Dr. Christina M. Coughlin, also known as Chris, BS, MD, PH D., was Head of Research and Development of Avacta Group Plc from February 1, 2024 and serves as its Chief Executive Officer from May 01, 2024 and...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Christina Coughlin	CEO, Interim Chief Medical Officer and Director	less than a year	UK£53.00k	0.014% € 31.7k
Tony Gardiner	CFO & Company Secretary	8.8yrs	UK£409.00k	0.0022% € 5.2k
Emma Wright	Group In-House Counsel	no data	Veri yok	Veri yok
Michael Vinegrad	Group Communications Director	3.8yrs	Veri yok	Veri yok
R. Slater	Chief Operating Officer of Diagnostics	8.2yrs	UK£69.00k	Veri yok
David Wilson	Chief Commercial Officer of Diagnostics	1.8yrs	Veri yok	Veri yok
Karen Harrison	Chief Operating Officer of Therapeutics Division	1.6yrs	Veri yok	Veri yok
Anne McGurk	Joint Managing Director of Launch Diagnostics	1.5yrs	Veri yok	Veri yok
Ian Jones	Joint Managing Director of Launch Diagnostics	1.5yrs	Veri yok	Veri yok
Simon Bennett	Chief Business Officer of Therapeutics	less than a year	Veri yok	Veri yok
Sebastien Goenen	Chief Operating Officer of Coris BioConcept	1.6yrs	Veri yok	Veri yok
Lena Kastl	Managing Director of Launch Diagnostics Deutschland GmbH	less than a year	Veri yok	Veri yok

1.6yrs

Ortalama Görev Süresi

54yo

Ortalama Yaş

Deneyimli Yönetim: RTQ1 'un yönetim ekibi deneyimli olarak kabul edilmiyor ( 1.6 yıl), bu da yeni bir ekibin varlığını gösteriyor.

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Christina Coughlin	CEO, Interim Chief Medical Officer and Director	2.6yrs	UK£53.00k	0.014% € 31.7k
Trevor Nicholls	Independent Non-Executive Director	11.2yrs	UK£47.00k	0.029% € 68.0k
Darlene Deptula-Hicks	Non Executive Director	less than a year	Veri yok	Veri yok
Shaun Chilton	Non-Executive Independent Chairman	1.3yrs	UK£26.00k	0.011% € 25.3k
Mark A. Goldberg	Independent Non-Executive Director	3.2yrs	UK£53.00k	Veri yok
Paul Fry	Independent Non-Executive Director	4.7yrs	UK£47.00k	Veri yok
Alan Ho	Member of Scientific Advisory Board	less than a year	Veri yok	Veri yok
William Tap	Chairman of Scientific Advisory Board	less than a year	Veri yok	Veri yok
Robert Metcalf	Member of Scientific Advisory Board	less than a year	Veri yok	Veri yok
Andrea Napolitano	Member of Scientific Advisory Board	less than a year	Veri yok	Veri yok
Lee Cranmer	Member of Scientific Advisory Board	less than a year	Veri yok	Veri yok
Anthony Yu	Member of Scientific Advisory Board	less than a year	Veri yok	Veri yok

0.3yrs

Ortalama Görev Süresi

62.5yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: RTQ1 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilmiyor ( 0.3 yıllık ortalama görev süresi), bu da yeni bir yönetim kurulu olduğunu gösteriyor.

Avacta Group Yönetim

Yönetim kriter kontrolleri 1/4

Anahtar bilgiler

Son yönetim güncellemeleri

Avacta Group plc Appoints Michelle Morrow as Chief Scientific Officer, Effective November 4, 2024

Avacta Group plc Announces Board Changes

Avacta Group plc Announces Board Changes

Avacta Group Plc, Annual General Meeting, Jun 26, 2024

Avacta Group plc Announces Chief Executive Officer Changes

Avacta Group plc Announces Chief Executive Officer Changes

Recent updates

Avacta Reports Pipeline Advances with Two Novel Programs at the EORTC-NCI-AACR Molecular Targets Symposium in Barcelona

Avacta Group plc Expands Its Pipeline with Two Novel Assets Developed Using Its Pre|CISION Platform

Avacta Group plc Appoints Michelle Morrow as Chief Scientific Officer, Effective November 4, 2024

Avacta to Unveil Pipeline Expansion and Novel, Next-Generational Targeted Cancer Therapy Programs At 2024 Eortc-Nci-Aacr Symposium

First half 2024 earnings released: UK£0.038 loss per share (vs UK£0.043 loss in 1H 2023)

New major risk - Financial position

Avacta Group plc Reports Updated Phase 1 Data of Ava6000 At the European Society for Medical Oncology Congress Demonstrating Multiple Ongoing, Durable Responses in Solid Tumors

Avacta Group Plc to Report First Half, 2024 Results on Sep 30, 2024

Avacta Group plc Announces Board Changes

Avacta Group plc Announces Board Changes

Avacta Group Plc, Annual General Meeting, Jun 26, 2024

Avacta Group plc Announces Successful Completion of First Cohort and Dosing of Three Patients of the Second Cohort in Arm 2 of Avacta's Ava6000 Phase 1 Trial

Avacta Group plc Announces Chief Executive Officer Changes

Avacta Group plc Announces Chief Executive Officer Changes

Full year 2023 earnings released: UK£0.091 loss per share (vs UK£0.15 loss in FY 2022)

New minor risk - Financial data availability

Avacta Group plc Reports Data from the Ongoing Phase 1 Clinical Trial of AVA6000 At the AACR Annual Meeting

Avacta Group Plc Announces Update on AVA6000 Phase 1a Clinical Trial Progress

Avacta Group Plc has completed a Follow-on Equity Offering in the amount of £5.448474 million.

Avacta Group Plc has completed a Follow-on Equity Offering in the amount of £5.448474 million.

Avacta Group Plc has filed a Follow-on Equity Offering in the amount of AUD 20.560243 million.

Avacta Group plc Announces Appointment of Christina Coughlin as Head of Research and Development and Resignation of Fiona Mclaughlin as Chief Scientific Officer

Avacta Group plc Appoints Simon Bennett as Chief Business Officer of the Therapeutics Division

Avacta Group plc Provides Detailed Pre-Clinical, Clinical and Pharmacokinetic Data from the Phase 1A Dose Escalation Study

First half 2023 earnings released: UK£0.043 loss per share (vs UK£0.036 loss in 1H 2022)

New major risk - Financial position

Avacta Group Plc Announces Management Changes

Avacta Group plc Announces Successful Completion of ALS-6000-101 Sixth Dose Escalation

Avacta Group Plc to Report First Half, 2023 Results on Sep 28, 2023

New major risk - Share price stability

New major risk - Share price stability

Avacta Announces Successful Completion of Fifth Dose Escalation in Ava6000 Phase 1 Clinical Study

Avacta Group plc Appoints Shaun Chilton to the Board as Non-Executive Director

Avacta Group Plc (AIM:AVCT) acquired Unknown minority stake in AffyXell Therapeutics Co., Ltd. from Daewoong pharmaceutical Co.,Ltd (KOSE:A069620).

Avacta Group Plc, Annual General Meeting, Jun 28, 2023

Avacta Group plc acquired Coris Bioconcept SRL for £10.4 million.

Full year 2022 earnings released: UK£0.15 loss per share (vs UK£0.11 loss in FY 2021)

Avacta Group plc Announces Successful Completion of Fourth Dose Escalation in AVA6000 Phase 1 Clinical Study

High number of new and inexperienced directors

Avacta Group Plc (AIM:AVCT) conditionally agreed to acquire Launch Diagnostics Holdings Limited for £37 million.

First half 2022 earnings released: UK£0.036 loss per share (vs UK£0.041 loss in 1H 2021)

Avacta Group Plc to Report First Half, 2022 Results on Sep 29, 2022

Avacta Group plc Announces Phase I Study of AVA6000 Advances to Fourth Cohort

High number of new and inexperienced directors

Avacta Group Plc announced that it has received funding

Avacta Group Plc Announces Second Dose Escalation in the Phase I Clinical Study of AVA6000 Pro-Doxorubicin

Avacta Group Plc, Annual General Meeting, Jun 23, 2022

Avacta Group Plc Relocates its Therapeutics Division to New Headquarters at Scale Space, in Imperial College's White City Campus, London

Less than half of directors are independent

Full year 2021 earnings released: UK£0.11 loss per share (vs UK£0.084 loss in FY 2020)

Avacta Group Plc to Report Fiscal Year 2021 Results on Apr 06, 2022

Avacta Group Plc to Report Fiscal Year 2021 Results on Apr 06, 2022

Avacta Announces Dose Escalation in the Phase I Clinical Study of AVA6000 Pro-Doxorubicin

Avacta Group plc Selects Second Pre|Cision™ Pro-Drug Candidate for Development

Avacta Group plc Provides Update on AffiDX SARS-CoV-2 Antigen Lateral Flow Test and Detection of the Omicron Variant

Avacta Group Plc Announces AffiDX® SARS-CoV-2 Antigen Lateral Flow Test Has Received A CE Mark for Use as A Consumer Self-Test in the UK and EU

Avacta Group Plc Announces AffiDx® SARS-CoV-2 Antigen Lateral Flow Test Detects the Omicron Variant

Avacta Group plc Announces US Food and Drug Administration Approval of IND Application for AVA6000

First half 2021 earnings released: UK£0.041 loss per share (vs UK£0.037 loss in 1H 2020)

Avacta Group Plc Announces Pre-Clinical Development Milestone in LG Chem Life Sciences Partnership

Avacta Group plc Provides Update on AffiDX Lateral Flow Test

Avacta Announces Registration of its AffiDX SARS-CoV-2 Antigen Lateral Flow Test in EU

MHRA Confirms Registration of Avacta’s Affidx® SARS-CoV-2 Antigen Lateral Flow Test

Avacta Group plc Provides an Update on Lateral Flow Test Regulatory Submissions

Full year 2020 earnings released: UK£0.084 loss per share (vs UK£0.092 loss in FY 2019)

Full year 2020 earnings released: UK£0.084 loss per share (vs UK£0.092 loss in FY 2019)

Avacta Signs Diagnostic Licensing Deal with Biokit

Avacta Group plc Announces its AffiDX SARS-CoV-2 Rapid Antigen Lateral Flow Test Detects the Dominant New Variants of the Coronavirus

Avacta Announces Phase 1 Clinical Trial Authorisation (CTA) for AVA6000 Approved by MHRA